Evidence map›Paper›PMID 26425092›Full record

ReviewInternational journal of nanomedicine2015

Targeting cancer stem cells by using the nanoparticles.

In-Sun Hong, Gyu-Beom Jang, Hwa-Yong Lee, Jeong-Seok Nam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Cancer stem cells and strategies for targeted drug delivery.Drug delivery and translational research · 2021
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Why nanodiamond carriers manage to overcome drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2020
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

In-Sun HongLaboratory of Tumor Suppressor, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea ; Department of Molecular Medicine, School of Medicine, Gachon University, Incheon, Republic of Korea.
Gyu-Beom JangLaboratory of Tumor Suppressor, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea ; Department of Molecular Medicine, School of Medicine, Gachon University, Incheon, Republic of Korea.
Hwa-Yong LeeThe Faculty of Liberal Arts, Jungwon University, Chungbuk, Republic of Korea.
Jeong-Seok NamLaboratory of Tumor Suppressor, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea ; Department of Molecular Medicine, School of Medicine, Gachon University, Incheon, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) have been shown to be markedly resistant to conventional cancer treatments such as chemotherapy and radiation therapy. Therefore, therapeutic strategies that selectively target CSCs will ultimately lead to better cancer treatments. Currently, accessible conventional therapeutic agents mainly eliminate the bulk tumor but do not eliminate CSCs. Therefore, the discovery and improvement of CSC-targeting therapeutic agents are necessary. Nanoparticles effectively inhibit multiple types of CSCs by targeting specific signaling pathways (Wnt/β-catenin, Notch, transforming growth factor-β, and hedgehog signaling) and/or specific markers (aldehyde dehydrogenases, CD44, CD90, and CD133) critically involved in CSC function and maintenance. In this review article, we summarized a number of findings to provide current information about their therapeutic potential of nanoparticles in various cancer cell types and CSCs.

Indexed as

Molecular Targeted TherapyBiomarkers, TumorCarcinogenesisHumansNanoparticlesNeoplastic Stem CellsSignal TransductionBiomarkers, TumorALDHCD133CD44HedgehogNotchTGF-β signalingWnt/β-catenin

Identifiers

PMID26425092
PMCPMC4583536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.